Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Almonertinib + Pemetrexed in Resectable EGFR-Mutated NSCLC (Phase 2)
ChiCTR2600129562Phase 2Not yet recruiting
- Sponsor
- Yuebei People's Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Yuebei People's Hospital. Primary endpoint: Major Pathological Response (MPR). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600129562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129562.